PALB2 has made it over the first hurdle and is now included in the breast cancer clinical genetics arena but to extend current utility and have an impact on improving the clinical outcomes for carriers of PALB2 mutations and incorporate use of this genetic information into precision public health initiatives, additional data is still urgently required. This evidence concerns the gene PALB2 and breast carcinoma.